# MYF6

## Overview
MYF6, or myogenic factor 6, is a gene that encodes a protein belonging to the basic helix-loop-helix (bHLH) transcription factor family, which is integral to muscle differentiation and development. The MYF6 protein, also known as MRF4, is a myogenic regulatory factor (MRF) that plays a pivotal role in the regulation of muscle-specific gene expression, facilitating the differentiation of myoblasts into mature muscle fibers. It achieves this by binding to E-box sequences in DNA, thereby activating genes essential for muscle development (Zammit2017Function). MYF6 is predominantly expressed in mature myofibers and is involved in maintaining muscle homeostasis, as well as in processes such as myocyte fusion during muscle regeneration (Bataille2023Indoxyl). The gene's expression and function are critical for normal muscle physiology, and mutations in MYF6 have been linked to muscle-related disorders, highlighting its clinical significance (Kerst2000Heterozygous).

## Structure


## Function
MYF6, also known as myogenic factor 6 or MRF4, is a member of the myogenic regulatory factors (MRFs) family, which plays a crucial role in muscle differentiation and development. MYF6 is primarily involved in the regulation of muscle-specific gene expression, promoting the differentiation of myoblasts into mature muscle fibers. It functions by binding to E-box sequences in the DNA, activating muscle-specific genes (Zammit2017Function).

In healthy human cells, MYF6 is highly expressed in mature myofibers and is involved in maintaining muscle homeostasis. It represses genes associated with muscle hypertrophy, potentially through the inhibition of MEF2 activity, which is important for muscle growth and repair (Zammit2017Function). MYF6 is also crucial for myocyte fusion during myotube formation and muscle regeneration, playing a significant role in myocyte-myocyte and myocyte-myotube fusion during embryogenesis and repair (Bataille2023Indoxyl).

MYF6 is not expressed in quiescent satellite cells or mature muscle cells under normal conditions, except for its potential role in maintaining muscle fiber innervation and the satellite cell pool (Bataille2023Indoxyl). This regulatory function underscores its importance in muscle development and regeneration.

## Clinical Significance
Mutations and altered expression of the MYF6 gene have been associated with various muscle-related disorders. A heterozygous mutation in MYF6, specifically a 387G>T transversion resulting in an alanine to serine substitution (A112S), has been linked to myopathy and a severe form of Becker muscular dystrophy (BMD). This mutation affects the protein's ability to bind DNA and transactivate target promoters, leading to reduced protein-protein interaction and MYF6 haploinsufficiency. The mutation was identified in a father and son, both exhibiting myopathy and an aggravated BMD phenotype, suggesting that MYF6 may act as a modifier gene influencing the severity of muscular disorders (Kerst2000Heterozygous).

In the context of hematologic malignancies, MYF6 is significantly overexpressed in hairy cell leukemia (HCL) compared to its variant (HCLv) and other B-cell malignancies. This overexpression is associated with hypomethylation of the MYF6 gene in HCL, which correlates with higher expression levels. MYF6 expression has been proposed as a potential biomarker for minimal residual disease detection in HCL and chronic lymphocytic leukemia (CLL), although its sensitivity and specificity require further investigation (Arons2020Expression).

## Interactions
MYF6, also known as myogenic factor 6, is involved in various interactions with proteins and nucleic acids that are crucial for its role in muscle differentiation. MYF6 is part of the basic helix-loop-helix (bHLH) transcription factor family, which is essential for DNA binding and protein dimerization. It interacts with other proteins such as E12 and E47, which are ubiquitous factors that facilitate its function in muscle-specific gene activation (Braun1990Myf6). 

The MYF6 protein can activate muscle-specific gene promoters in non-muscle cells, indicating its role in transcriptional control through DNA-protein interactions. However, MYF6 shows weak binding to DNA sequences that other myogenic factors like Myf-3, Myf-4, and Myf-5 bind strongly to, suggesting a lower affinity for these sequences (Braun1990Myf6). This weak interaction might be due to MYF6's inability to form homodimers, unlike other Myf proteins, indicating that it may require interaction with other proteins to exert its function (Braun1990Myf6).

A specific mutation, A112S, within the MYF6 gene's bHLH domain, has been shown to impair its ability to interact with the protein binding partner E2-2 and abolish DNA binding, highlighting the importance of these interactions for its function (Kerst2000Heterozygous).


## References


[1. (Kerst2000Heterozygous) Birgit Kerst, Detlev Mennerich, Markus Schuelke, Gisela Stoltenburg-Didinger, Arpad von Moers, Reinhart Gossrau, Frank K.H van Landeghem, Astrid Speer, Thomas Braun, and Christoph Hübner. Heterozygous myogenic factor 6 mutation associated with myopathy and severe course of becker muscular dystrophy. Neuromuscular Disorders, 10(8):572–577, December 2000. URL: http://dx.doi.org/10.1016/s0960-8966(00)00150-4, doi:10.1016/s0960-8966(00)00150-4. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0960-8966(00)00150-4)

[2. (Zammit2017Function) Peter S. Zammit. Function of the myogenic regulatory factors myf5, myod, myogenin and mrf4 in skeletal muscle, satellite cells and regenerative myogenesis. Seminars in Cell &amp; Developmental Biology, 72:19–32, December 2017. URL: http://dx.doi.org/10.1016/j.semcdb.2017.11.011, doi:10.1016/j.semcdb.2017.11.011. This article has 540 citations.](https://doi.org/10.1016/j.semcdb.2017.11.011)

[3. (Bataille2023Indoxyl) Stanislas Bataille, Nathalie McKay, Laetitia Koppe, Alice Beau, Bérengère Benoit, Marc Bartoli, Nathalie Da Silva, Stéphane Poitevin, Julien Aniort, Rania Chermiti, Stéphane Burtey, and Laetitia Dou. Indoxyl sulfate inhibits muscle cell differentiation via myf6/mrf4 and myh2 downregulation. Nephrology Dialysis Transplantation, 39(1):103–113, June 2023. URL: http://dx.doi.org/10.1093/ndt/gfad123, doi:10.1093/ndt/gfad123. This article has 2 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/ndt/gfad123)

[4. (Arons2020Expression) Evgeny Arons, Hong Zhou, Mark Sokolsky, Daniel Gorelik, Katherine Potocka, Sarah Davies, Erin Fykes, Katherine Still, Daniel C. Edelman, Yonghong Wang, Paul S. Meltzer, Mark Raffeld, Adrian Wiestner, Liqiang Xi, Hao-Wei Wang, Maryalice Stetler-Stevenson, Constance Yuan, and Robert J. Kreitman. Expression of the muscle-associated gene myf6 in hairy cell leukemia. PLOS ONE, 15(2):e0227586, February 2020. URL: http://dx.doi.org/10.1371/journal.pone.0227586, doi:10.1371/journal.pone.0227586. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0227586)

[5. (Braun1990Myf6) T. Braun, E. Bober, B. Winter, N. Rosenthal, and H.H. Arnold. Myf-6, a new member of the human gene family of myogenic determination factors: evidence for a gene cluster on chromosome 12. The EMBO Journal, 9(3):821–831, March 1990. URL: http://dx.doi.org/10.1002/j.1460-2075.1990.tb08179.x, doi:10.1002/j.1460-2075.1990.tb08179.x. This article has 348 citations.](https://doi.org/10.1002/j.1460-2075.1990.tb08179.x)